Fredrik Nils Albach

8PUBLICATIONS
53CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunityHaematological tumoursRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 27, 2026
CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial.

|Sep 09, 2024
Phase 1 Trials of Gatralimab, a Next-Generation Humanized Anti-CD52 Monoclonal Antibody, in Participants with Progressive Multiple Sclerosis.

Fredrik N Albach, Christian Geier, Christian Keicher

|Jul 05, 2024
Prophylactic antibodies inhibit spike-specific T and B cell responses after COVID-19 vaccination.

Henrik E Mei, Axel Ronald Schulz, Heike Hirseland

|Jan 04, 2023
Type of vaccine and immunosuppressive therapy but not diagnosis critically influence antibody response after COVID-19 vaccination in patients with rheumatic disease.

Leonie Maria Frommert, Amanthi Nadira Arumahandi de Silva, Jan Zernicke

|Oct 10, 2022
Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination.

Elisa Habermann, Lutz Gieselmann, Pinkus Tober-Lau

|Mar 15, 2022
Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases.

Amanthi Nadira Arumahandi de Silva, Leonie Maria Frommert, Fredrik N Albach

Pageof 2

Frequent Collaborators

6 joint publications

Robert Biesen

5 joint publications

Gerd-Rüdiger Burmester

4 joint publications

Alexander Ten Hagen

4 joint publications

Jan Zernicke